No Detail Found!

Erythropoietin induced hypertension

Author(s)
Bushra Moiz Department of Hematology, Medicare Laboratory, Karachi, Pakistan
Khalid Zafar Hashmi Department of Pathology, Liaquat National Hospital, Karachi, Pakistan
Iffat Yazdani Department of Nephrology, Liaquat National Hospital, Karachi, Pakistan
Abstract
  Hypertension has frequently been reported in association with Erythropoietin (EPO) use in-patients with renal failure. However, the relation between the two is complex, as chronic renal failure itself is associated with numerous cardiovascular complications including hypertension. The present clinical trial was undertaken to appreciate this unwanted effect of EPO in 24 hemodialysed patients with end stage renal disease. Out of them, 12 were hypertensives already receiving anti-hypertensive medication at the start of EPO therapy while rest were normotensive. These patients were randomly divided into group A and B, each had 12 patients (6 hypertensive and 6 normotensive). Group A received EPO in dose of 40 units/ kg body weight subcutaneously twice a week while group B was given double dose. The blood pressures of all the patients were noted before and during 10 weeks of EPO treatment, their hematocrit, hemoglobin, iron profile and blood chemistry were also monitored. Only 3 hypertensive patients receiving 80 u/kg EPO showed worsening of their blood pressures. No significant pressure changes were observed in normotensives with either EPO dosage or in hypertensive patients receiving low dose EPO. Our study showed that low dose EPO therapy could effectively be used to reverse anemia in renal failure patients without significantly altering their blood pressures. However, a minority of already hypertensive patients might show a worsening of their blood pressures with higher doses of EPO.
Publication Details
Page(s) 317-320
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 10, Issue: 9, Year: 2000

Request the full text from PASTIC

Keywords
Erythropoietin. Blood pressure. Hypertension, renal. Kidney failure, chronic End-stage renal disease.
References
Mauer RF .1994 .The effect of Epoietin beta on the need for transfusion in very low birth weight infants. NEngJMed, 330 : 1173-8.
Ludwig H,Fritz E,Leitgeb C .1993 .et a! Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Annats ofOncol, 4 : 161-7.
. .Cardiovascular system in chronic renal failure. The impact of anemia and its correction with erythropoietin in Overview of literature related to erythropoietin 1993; 1-4. , : .
Al MomenAK,Garder AM .1991 .Low dose danazol is effective in management of erythropoietin induced thrombosis. ThrombPes, 64(5) : 527-32.
Savazi GM .1988 .Pathogenesis of cerebral atrophy in uremia. Nephron, 49 : 94-103.
Casati F,PasseriniP F .1987 .Benefits and risks of protracted treatment With human recombinant erythropoietin in-patients having hemodialysis. BMJ, 295 : 1017-20.
Abdul-Hadi NM .1989 .Recombinant human erythropoietin, correction of anemia dialysis efficiency, waste retention and chronic dose variables. ASA/0 Trans, 35 : 513-5.
EschbachJW. Ergie JC .1987 .DowningAIR Correction of anemia of end stage renal disease with recombinant human erythropoietin. NewEng JMed, 316 : 73-8.
Ganelloeras C,Leskopf W,Sheldon S,Forcade J . .Experience of pain after sub cutaneous administration of different preparation of Recombinant Human Erythropoietin: a randomized double blind cross over study. Ch'nNephro!\, 974 : 296.
Schaefer PM,Strauer RE,Heidland A .1988 .Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. AnnJNephro!, 8 : 449-53.
NonnastDaniel B. Crentzig A,Kuhn K .1988 .! Effort of treatment with recombinant human erythropoietin on peripheral hemodialysis and oxygenation. , 66 : 185-94.
Roger SD,Fluck RJ,Me MahonAC,Drawnay A,Raine ABG . .Blood pressure, erythropoietin and intracellular calcium in experimental hypertension and uremia. AbstractEDTA1992, : .
Yamakado M,Umezo M,Nagano M,Tagawa H M .1991 .Mechanism of hypertension induced by erythropoietin in-patients on hemodialysis. din Invest Med, 14(6) : 623-9.
Bode Boger SM,Boger RH,Kuhn M,Radermacher J,Frolich JC .1992 .Endothelin release and shift in prostaglandin balance are involved in modulation of vascular tone by recombinant human erythropoietin. J Cardio Vase Pharmacol, 20(Suppl 12) : .
.1987 .Recombinant human erythropoietin therapy in hemodialysis patients. Dose determination and clinical experience. NephrolDial Transplant, 2 : 238-42.
.1991 .Experience of erythropoietin in anemia of end stage renal disease. JPMA, 41 : 310-12.
.1994 .Once weekly sub cutaneous administration of erythropoietin in hemodialysis patients. JPMA, 44 : 88-90.
. .Effect of recombinant human erythropoietin therapy on blood pressure changes in hemodialysis. Am JNephrol 23-6, : .
El-Shahawy MA,Akmal M .1994 .eta! Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregration in hemodialysis patients. Clinical Nephrology, 41 : 308-13.
Eschbach JW,Dowing MR,Ergie JC,Browne JK,Adamson JW .1989 .USA Multicenter clinical trial with Recombinant Human Erythropoietin. , 76 : 160-5.
Pippard MJ,Hoffbrand V.,Iron V. .1999 .. In Postgraduate Haematology. 4th ed: Butterworth-Heinemann, : 33.
Tielmans C,Goldman M,Vanderweghem JL .1989 .Disorders of iron metabolism in uremic patients. Seminars in Dialysis, 2 : 163-71.
.2000 .Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients. Recommendations for a change in management. Am JKidDis, 35(6) : 1226-37.
Walker R .1999 .general management of end stage renal disease. 2®fc. , : 1429-32.
Krantz AT .1999 .Screening plasma aluminum levels in relation to aluminum bone disease among asymptomatic dialysis patients. Am J Kid Dis, 34(4) : 688-93.
Tarng DC . .HuangTP. Recombinant human erythropoietin resistance in iron replete hemodialysis patients: role of Aluminum toxicity. Am J Nephrol, 8(1) : 1-8.
0

Citations

0

Downloads

48

Views